Abpro Holdings Inc
ABP
Company Profile
Business description
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
Contact
68 Cummings Park Drive
WoburnMA01801
USAT: +1 800 396-5890
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
CBA earnings: The only thing that puzzles us is the share price
No surprises in fiscal 2025 earnings.
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors too optimistic about ASX growth story
Investors have gotten ahead of themselves with shares trading at a 94% premium to fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,103.10 | 47.20 | -0.52% |
| CAC 40 | 7,804.97 | 51.55 | 0.66% |
| DAX 40 | 24,185.59 | 160.81 | 0.67% |
| Dow JONES (US) | 44,767.28 | 308.67 | 0.69% |
| FTSE 100 | 9,165.23 | 17.42 | 0.19% |
| HKSE | 25,613.67 | 643.99 | 2.58% |
| NASDAQ | 21,701.54 | 19.64 | 0.09% |
| Nikkei 225 | 43,274.67 | 556.50 | 1.30% |
| NZX 50 Index | 12,766.54 | 6.86 | 0.05% |
| S&P 500 | 6,453.32 | 7.56 | 0.12% |
| S&P/ASX 200 | 8,827.10 | 53.70 | -0.60% |
| SSE Composite Index | 3,683.46 | 17.55 | 0.48% |